Last reviewed · How we verify
Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke (ReMEDy1)
This is a Phase II study to assess the safety and tolerability of DM199 in acute ischemic stroke patients. The study will be randomized, placebo controlled at multiple centers.
Details
| Lead sponsor | DiaMedica Therapeutics Inc |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 92 |
| Start date | Fri Jan 19 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Jan 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Acute Ischemic Stroke
Interventions
- Recombinant human tissue kallikrein
- Placebo
Countries
Australia